Juan Jesús Fernández Alba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan Jesús Fernández Alba has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Luis Javier Moreno Corral
Department of Nursing and Physiotherapy, University of Cádiz (UCA), Avda. Ana de Viya, 52, 11009 Cádiz, Spain
11 shared publications Carmen González Macías
Department of Maternal and Child Health and Radiology, University of Cádiz, Cádiz, Spain
8 shared publications- María Castillo Lara
Department of Obstetrics and Gynaecology, University Hospital of Puerto Real, 11-510 Cadiz, Spain
8 shared publications Florentino Carral San Laureano
Hospital Universitario Puerto Real
7 shared publications- Ángel Vilar Sánchez
Department of Obstetrics and Gynecology, University Hospital of Puerto Real, Ctra. Nacional IV, Km 665, 11510 Puerto Real, Spain
7 shared publications Ana Isabel Jiménez Millán
Affiliation Department of Endocrinology and Nutrition, Hospital Universitario de Puerto Real, Cádiz, Spain
5 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (11) , e0001828
Logistic regression withstands comparison with machine learning for thyroid nodule malignancy risk stratification under strict temporal validation
Ultrasound risk-stratification systems (ACR TI-RADS, EU-TIRADS, ATA 2015) guide fine-needle aspiration decisions for thyroid nodules but do not integrate clinical or biochemical information. Multivariable logistic regression (LR) models incorporating these variables provide individualised malignancy probability estimates, and machine learning (ML) algorithms have been proposed as potential improvements, but rigorous comparative evidence under temporal validation is scarce. We conducted a single-centre retrospective cohort study of 861 thyroidectomies (2010–2023), split chronologically (training: before 2019, n = 432, 94 malignant; test: 2019 onwards, n = 429, 92 malignant). An LR model using the specification of a previously published and externally validated model — with coefficients re-estimated in the training cohort — was compared head-to-head with Random Forest (RF), XGBoost (XGB), Bagged CART, and a multilayer perceptron (MLP) trained on the same predictors. Performance was assessed by discrimination (ROC-AUC and precision-recall AUC), calibration (Brier score, calibration slope and intercept), and clinical utility (decision curve analysis), with operating characteristics reported at the pre-specified 9.55% probability threshold. LR achieved an AUC of 0.838 (95% CI 0.789–0.884), closely matching the published external validation of the original model (0.84). RF (AUC 0.843, p = 0.76) and XGB (AUC 0.844, p = 0.69) were statistically indistinguishable from LR; Bagged CART (0.821, p = 0.40) was non-significantly inferior; the MLP (0.768, p < 0.001) performed significantly worse. LR showed the highest precision-recall AUC (0.672) and good calibration without post-hoc adjustment (slope 1.12, 95% CI 0.91–1.43). LR, RF, XGB and Bagged CART discriminated significantly better than the ATA 2015 classification (AUC 0.750; DeLong p ≤ 0.002), whereas the MLP did not differ significantly from it (p = 0.45). In exploratory subgroup analyses by Bethesda category, nodule size, and age, no evidence of a consistent ML advantage was observed, although several subgroups were underpowered. SHAP importance rankings from RF and XGB showed broadly similar global orderings to the LR coefficients (ρ = 0.71 and 0.77). In this single-centre surgical cohort with a moderate sample size and routinely collected structured predictors, none of the evaluated ML algorithms demonstrated improved performance over a well-specified LR model.
- 11 November 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (11) , e0001828
Open AccessLogistic regression withstands comparison with machine learning for thyroid nodule malignancy risk stratification under strict temporal validation
Ultrasound risk-stratification systems (ACR TI-RADS, EU-TIRADS, ATA 2015) guide fine-needle aspiration decisions for thyroid nodules but do not integrate clinical or biochemical information. Multivariable logistic regression (LR) models incorporating these variables provide individualised malignancy probability estimates, and machine learning (ML) algorithms have been proposed as potential improvements, but rigorous comparative evidence under temporal validation is scarce. We conducted a single-centre retrospective cohort study of 861 thyroidectomies (2010–2023), split chronologically (training: before 2019, n = 432, 94 malignant; test: 2019 onwards, n = 429, 92 malignant). An LR model using the specification of a previously published and externally validated model — with coefficients re-estimated in the training cohort — was compared head-to-head with Random Forest (RF), XGBoost (XGB), Bagged CART, and a multilayer perceptron (MLP) trained on the same predictors. Performance was assessed by discrimination (ROC-AUC and precision-recall AUC), calibration (Brier score, calibration slope and intercept), and clinical utility (decision curve analysis), with operating characteristics reported at the pre-specified 9.55% probability threshold. LR achieved an AUC of 0.838 (95% CI 0.789–0.884), closely matching the published external validation of the original model (0.84). RF (AUC 0.843, p = 0.76) and XGB (AUC 0.844, p = 0.69) were statistically indistinguishable from LR; Bagged CART (0.821, p = 0.40) was non-significantly inferior; the MLP (0.768, p < 0.001) performed significantly worse. LR showed the highest precision-recall AUC (0.672) and good calibration without post-hoc adjustment (slope 1.12, 95% CI 0.91–1.43). LR, RF, XGB and Bagged CART discriminated significantly better than the ATA 2015 classification (AUC 0.750; DeLong p ≤ 0.002), whereas the MLP did not differ significantly from it (p = 0.45). In exploratory subgroup analyses by Bethesda category, nodule size, and age, no evidence of a consistent ML advantage was observed, although several subgroups were underpowered. SHAP importance rankings from RF and XGB showed broadly similar global orderings to the LR coefficients (ρ = 0.71 and 0.77). In this single-centre surgical cohort with a moderate sample size and routinely collected structured predictors, none of the evaluated ML algorithms demonstrated improved performance over a well-specified LR model.
- Open Access
- 20 September 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-10
Confounding by indication in the evaluation of neoadjuvant chemotherapy: a sequential Cox analysis of an eight-year single-centre breast cancer cohort
Purpose: Neoadjuvant chemotherapy (NACT) is reserved for tumours with a worse prognosis, introducing confounding by indication. Using sequentially adjusted Cox models to display confounding step by step, we assessed prognostic factors and the role of neoadjuvant therapy in a single-centre breast cancer cohort. Methods: Retrospective study of 461 women treated at a single Spanish hospital (2016–2018) and followed to March 2026 (median 7.3 years; 456 in survival analyses). Overall (OS) and disease-free survival (DFS) were estimated by the Kaplan–Meier and Cox regression methods; proportional hazards were checked with Schoenfeld residuals and missing data handled by multiple imputation. Results: Five-year OS and DFS were 89.7% and 86.0%. Independent prognostic factors were stage III–IV (HR 3.9), triple-negative subtype (HR 2.4) and adjuvant radiotherapy (HR 0.32). The apparent adverse effect of neoadjuvant therapy (univariable HR 2.35) disappeared after stage adjustment (HR 1.6; p = 0.17), with the same pattern for DFS; treated women differed chiefly in stage III–IV (60% vs. 14%; standardised mean difference 1.09). Recovering missing histological grade from source reports abolished its apparent prognostic effect (HR 1.40, 0.82–2.39). The triple-negative excess risk was concentrated in the first three years (HR 4.8 vs 0.4; interaction p = 0.020). Conclusions: After adjustment for stage and tumour burden, the apparent adverse effect of neoadjuvant therapy is largely explained by confounding by indication rather than treatment although the small treated subgroup cannot exclude a modest residual effect. Sequentially adjusted Cox models display the confounding pathway explicitly, complementing propensity-score approaches.
- 20 September 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-10
Open AccessConfounding by indication in the evaluation of neoadjuvant chemotherapy: a sequential Cox analysis of an eight-year single-centre breast cancer cohort
Purpose: Neoadjuvant chemotherapy (NACT) is reserved for tumours with a worse prognosis, introducing confounding by indication. Using sequentially adjusted Cox models to display confounding step by step, we assessed prognostic factors and the role of neoadjuvant therapy in a single-centre breast cancer cohort. Methods: Retrospective study of 461 women treated at a single Spanish hospital (2016–2018) and followed to March 2026 (median 7.3 years; 456 in survival analyses). Overall (OS) and disease-free survival (DFS) were estimated by the Kaplan–Meier and Cox regression methods; proportional hazards were checked with Schoenfeld residuals and missing data handled by multiple imputation. Results: Five-year OS and DFS were 89.7% and 86.0%. Independent prognostic factors were stage III–IV (HR 3.9), triple-negative subtype (HR 2.4) and adjuvant radiotherapy (HR 0.32). The apparent adverse effect of neoadjuvant therapy (univariable HR 2.35) disappeared after stage adjustment (HR 1.6; p = 0.17), with the same pattern for DFS; treated women differed chiefly in stage III–IV (60% vs. 14%; standardised mean difference 1.09). Recovering missing histological grade from source reports abolished its apparent prognostic effect (HR 1.40, 0.82–2.39). The triple-negative excess risk was concentrated in the first three years (HR 4.8 vs 0.4; interaction p = 0.020). Conclusions: After adjustment for stage and tumour burden, the apparent adverse effect of neoadjuvant therapy is largely explained by confounding by indication rather than treatment although the small treated subgroup cannot exclude a modest residual effect. Sequentially adjusted Cox models display the confounding pathway explicitly, complementing propensity-score approaches.
- Open Access
- 26 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2718
Differential Serum MicroRNA Profiling in Benign and Malignant Ovarian Tumours: An Exploratory Study Identifying hsa-miR-200c-3p as a Candidate Diagnostic Biomarker
Background/Objectives: Preoperative discrimination of benign from malignant adnexal masses remains a major clinical challenge, and circulating microRNAs (miRNAs) are candidate non-invasive biomarkers. This exploratory, hypothesis-generating study—not a diagnostic validation study—evaluated serum hsa-miR-200c-3p as a candidate diagnostic biomarker for ovarian malignancy. Methods: Serum from 39 women with an adnexal mass and a surgical indication (20 benign, 19 malignant), all with histological confirmation, was analysed. Of 179 assayed miRNAs, 178 were tested for differential expression (miR-103a-3p as endogenous reference) using the Mann–Whitney U test with Benjamini–Hochberg false-discovery-rate (FDR) correction; hsa-miR-200c-3p, a pre-specified miR-200 family candidate, was evaluated by ROC analysis and compared with, and adjusted for, CA 125, HE4 and age. Results: The malignant group was substantially older and more frequently postmenopausal. Thirty-eight miRNAs were significant after FDR correction; hsa-miR-200c-3p was up-regulated in malignancy. In the complete-case analysis restricted to the 35 participants with a detectable marker (20 benign, 15 malignant), the AUC was 0.893 (95% CI 0.76–0.99); however, four high-grade serous carcinomas showed undetectable serum hsa-miR-200c-3p, and when these were included and imputed as low expression (all-case analysis, n = 39) the AUC fell to 0.705 (95% CI 0.51–0.88). hsa-miR-200c-3p did not demonstrate statistically superior performance to HE4 (AUC 0.93) or CA 125 (0.89), with overlapping confidence intervals; any incremental value beyond established markers and age was modest and exploratory. Conclusions: Serum hsa-miR-200c-3p is a preliminary candidate that requires prospective, age-matched, adequately powered validation with pre-specified assays and analysis plans.
- 26 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2718
Open AccessDifferential Serum MicroRNA Profiling in Benign and Malignant Ovarian Tumours: An Exploratory Study Identifying hsa-miR-200c-3p as a Candidate Diagnostic Biomarker
Background/Objectives: Preoperative discrimination of benign from malignant adnexal masses remains a major clinical challenge, and circulating microRNAs (miRNAs) are candidate non-invasive biomarkers. This exploratory, hypothesis-generating study—not a diagnostic validation study—evaluated serum hsa-miR-200c-3p as a candidate diagnostic biomarker for ovarian malignancy. Methods: Serum from 39 women with an adnexal mass and a surgical indication (20 benign, 19 malignant), all with histological confirmation, was analysed. Of 179 assayed miRNAs, 178 were tested for differential expression (miR-103a-3p as endogenous reference) using the Mann–Whitney U test with Benjamini–Hochberg false-discovery-rate (FDR) correction; hsa-miR-200c-3p, a pre-specified miR-200 family candidate, was evaluated by ROC analysis and compared with, and adjusted for, CA 125, HE4 and age. Results: The malignant group was substantially older and more frequently postmenopausal. Thirty-eight miRNAs were significant after FDR correction; hsa-miR-200c-3p was up-regulated in malignancy. In the complete-case analysis restricted to the 35 participants with a detectable marker (20 benign, 15 malignant), the AUC was 0.893 (95% CI 0.76–0.99); however, four high-grade serous carcinomas showed undetectable serum hsa-miR-200c-3p, and when these were included and imputed as low expression (all-case analysis, n = 39) the AUC fell to 0.705 (95% CI 0.51–0.88). hsa-miR-200c-3p did not demonstrate statistically superior performance to HE4 (AUC 0.93) or CA 125 (0.89), with overlapping confidence intervals; any incremental value beyond established markers and age was modest and exploratory. Conclusions: Serum hsa-miR-200c-3p is a preliminary candidate that requires prospective, age-matched, adequately powered validation with pre-specified assays and analysis plans.
- Open Access
- 22 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (11) , 1584
Temporal External Validation of a Customized Fetal Body Mass Index Percentile Model for Neonatal Nutritional Status Assessment
Background/Objectives: Accurate identification of neonatal malnutrition is essential for optimizing perinatal care and reducing adverse outcomes. Traditional birthweight-based methods fail to account for body proportionality, limiting their ability to distinguish constitutionally small or large neonates from those with true nutritional abnormalities. We previously developed a customized fetal body mass index (cFBMI) percentile model that incorporates both weight and length, adjusted for maternal and fetal characteristics. This study aims to perform a temporal external validation of the cFBMI model following the Riley et al. framework, comparing its performance against the GROW customized birthweight model and the INTERGROWTH-21st population-based standard. Methods: A temporal validation study was conducted using singleton deliveries from Hospital Universitario de Puerto Real, Cádiz, Spain. The development cohort comprised 7864 deliveries (2002–2021); the validation cohort comprised 4441 deliveries (2022–2025). Inclusion criteria: singleton pregnancy, gestational age of 33–42 + 6 weeks, birthweight of 500–6000 g, known neonatal sex and length, and complete maternal data. The Ponderal Index (PI = weight/length3 × 100) stratified by sex and gestational age served as the gold standard (undernutrition: PI < p10; overnutrition: PI > p90). Discrimination was assessed using the area under the receiver operating characteristic curve (AUC) with bootstrap 95% confidence intervals (2000 iterations) and DeLong tests. Calibration was evaluated by comparing observed versus expected proportions across percentile categories. Clinical utility was assessed using decision curve analysis (DCA). Temporal stability was quantified by comparing AUCs and Brier scores between the development and validation cohorts. Results: In the validation cohort (n = 4441), cFBMI demonstrated superior discrimination for both undernutrition (AUC: 0.962) and overnutrition (AUC: 0.961) compared with GROW (AUC: 0.751 and 0.676, respectively) and INTERGROWTH-21st (AUC: 0.756 and 0.682, respectively); all DeLong comparisons p < 0.0001. The cFBMI exhibited excellent temporal stability (ΔAUC = −0.004 for undernutrition, +0.002 for overnutrition) and superior calibration (observed proportions: 9.6%/81.7%/8.8% vs. expected 10%/80%/10%; χ2 = 9.22, p = 0.010). The decision curve analysis confirmed the superior net benefit of cFBMI across all threshold probabilities. Conclusions: The customized fetal BMI percentile model demonstrates excellent and temporally stable discriminative performance in this single-institution temporal validation study, with superior calibration and apparent advantages in clinical utility as determined by decision curve analysis compared with existing methods. Its integration of body proportionality provides conceptual alignment with the Ponderal Index gold standard. These findings are promising but require confirmation through external multicenter validation before clinical implementation can be recommended. Although the mathematical relationship between the index test (weight/length2) and the reference standard (weight/length3) should be considered when interpreting the magnitude of discrimination metrics, validation against independent clinical outcomes is an essential next step. The cFBMI thus provides a proportionality-aware nutritional metric whose primary discriminative advantage over weight-based methods is realized at and beyond the moment of birth, and which is forward-compatible with emerging modalities for independent prenatal fetal length estimation.
- 22 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (11) , 1584
Open AccessTemporal External Validation of a Customized Fetal Body Mass Index Percentile Model for Neonatal Nutritional Status Assessment
Background/Objectives: Accurate identification of neonatal malnutrition is essential for optimizing perinatal care and reducing adverse outcomes. Traditional birthweight-based methods fail to account for body proportionality, limiting their ability to distinguish constitutionally small or large neonates from those with true nutritional abnormalities. We previously developed a customized fetal body mass index (cFBMI) percentile model that incorporates both weight and length, adjusted for maternal and fetal characteristics. This study aims to perform a temporal external validation of the cFBMI model following the Riley et al. framework, comparing its performance against the GROW customized birthweight model and the INTERGROWTH-21st population-based standard. Methods: A temporal validation study was conducted using singleton deliveries from Hospital Universitario de Puerto Real, Cádiz, Spain. The development cohort comprised 7864 deliveries (2002–2021); the validation cohort comprised 4441 deliveries (2022–2025). Inclusion criteria: singleton pregnancy, gestational age of 33–42 + 6 weeks, birthweight of 500–6000 g, known neonatal sex and length, and complete maternal data. The Ponderal Index (PI = weight/length3 × 100) stratified by sex and gestational age served as the gold standard (undernutrition: PI < p10; overnutrition: PI > p90). Discrimination was assessed using the area under the receiver operating characteristic curve (AUC) with bootstrap 95% confidence intervals (2000 iterations) and DeLong tests. Calibration was evaluated by comparing observed versus expected proportions across percentile categories. Clinical utility was assessed using decision curve analysis (DCA). Temporal stability was quantified by comparing AUCs and Brier scores between the development and validation cohorts. Results: In the validation cohort (n = 4441), cFBMI demonstrated superior discrimination for both undernutrition (AUC: 0.962) and overnutrition (AUC: 0.961) compared with GROW (AUC: 0.751 and 0.676, respectively) and INTERGROWTH-21st (AUC: 0.756 and 0.682, respectively); all DeLong comparisons p < 0.0001. The cFBMI exhibited excellent temporal stability (ΔAUC = −0.004 for undernutrition, +0.002 for overnutrition) and superior calibration (observed proportions: 9.6%/81.7%/8.8% vs. expected 10%/80%/10%; χ2 = 9.22, p = 0.010). The decision curve analysis confirmed the superior net benefit of cFBMI across all threshold probabilities. Conclusions: The customized fetal BMI percentile model demonstrates excellent and temporally stable discriminative performance in this single-institution temporal validation study, with superior calibration and apparent advantages in clinical utility as determined by decision curve analysis compared with existing methods. Its integration of body proportionality provides conceptual alignment with the Ponderal Index gold standard. These findings are promising but require confirmation through external multicenter validation before clinical implementation can be recommended. Although the mathematical relationship between the index test (weight/length2) and the reference standard (weight/length3) should be considered when interpreting the magnitude of discrimination metrics, validation against independent clinical outcomes is an essential next step. The cFBMI thus provides a proportionality-aware nutritional metric whose primary discriminative advantage over weight-based methods is realized at and beyond the moment of birth, and which is forward-compatible with emerging modalities for independent prenatal fetal length estimation.
- Open Access
- 27 December 2025
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (1) , 48
Advancement in continuous lactate determination in untreated human serum: multipolymer-based amperometric biosensor coupled with a low-cost 3D-printed microfluidic cell
Enzyme saturation in biosensing has been established as a main hindrance in lactate monitoring due to the high concentration of this species in biological samples. In this paper, a Sonogel–carbon transducer has been used for the fabrication of an amperometric biosensor for lactate (LA) determination. The sensor was constructed by immobilizing lactate oxidase as the bioreceptor and coating the electrode surface with multipolymer layers to minimize enzyme saturation and improve operational stability. This biosensor shows adequate sensitivity (1.74 µA mM − 1 cm -2 ) in a linear working range from 0.2 mM to 20 mM, suitable for physiological lactate concentrations in biofluids. The response of the biosensor was studied in physiological medium using several potential interferents (glucose, uric acid, dopamine, ascorbic acid, KCl, NaCl, CaCl 2 and BSA), demonstrating negligible interference from these common electroactive species. A microfluidic cell was designed and fabricated using polyethylene terephthalate glycol (PETG) through a rapid and low-cost 3D printing process. Finally, the prepared microfluidic cell was applied to lactate monitoring in flow regime using the biosensor with both synthetic and real untreated human serum samples, showing excellent correlation with two standard reference techniques and confirming its reliability. These results highlight the potential of the proposed microfluidic amperometric biosensor as a robust, real-time tool for biomedical lactate monitoring. Graphical Abstract
- 27 December 2025
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (1) , 48
Open AccessAdvancement in continuous lactate determination in untreated human serum: multipolymer-based amperometric biosensor coupled with a low-cost 3D-printed microfluidic cell
Enzyme saturation in biosensing has been established as a main hindrance in lactate monitoring due to the high concentration of this species in biological samples. In this paper, a Sonogel–carbon transducer has been used for the fabrication of an amperometric biosensor for lactate (LA) determination. The sensor was constructed by immobilizing lactate oxidase as the bioreceptor and coating the electrode surface with multipolymer layers to minimize enzyme saturation and improve operational stability. This biosensor shows adequate sensitivity (1.74 µA mM − 1 cm -2 ) in a linear working range from 0.2 mM to 20 mM, suitable for physiological lactate concentrations in biofluids. The response of the biosensor was studied in physiological medium using several potential interferents (glucose, uric acid, dopamine, ascorbic acid, KCl, NaCl, CaCl 2 and BSA), demonstrating negligible interference from these common electroactive species. A microfluidic cell was designed and fabricated using polyethylene terephthalate glycol (PETG) through a rapid and low-cost 3D printing process. Finally, the prepared microfluidic cell was applied to lactate monitoring in flow regime using the biosensor with both synthetic and real untreated human serum samples, showing excellent correlation with two standard reference techniques and confirming its reliability. These results highlight the potential of the proposed microfluidic amperometric biosensor as a robust, real-time tool for biomedical lactate monitoring. Graphical Abstract
- Open Access
- 24 April 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (9) , 1086
Pleural Fluid Biomarkers of Pediatric Parapneumonic Effusion
Background/Objectives: Parapneumonic pleural effusion (PPE) secondary to community-acquired pneumonia is the most common cause of pediatric pleural effusion. This study aimed to evaluate the pleural fluid characteristics of pediatric patients with PPE and to compare biomarkers between infants (1–12 months) and children (1–14 years). Methods: Fifty-four pediatric patients (14 infants and 40 children) with PPE were included. Pleural fluid samples were analyzed for white blood cell (WBC) count, glucose, total protein, lactate dehydrogenase (LDH), adenosine deaminase (ADA), and pH levels. Differences between age groups and correlations between age and pleural fluid biomarkers were assessed. Results: Most pediatric PPE cases exhibited biochemical characteristics consistent with pleural exudate: WBC > 1000 cells/µL, total protein > 3 g/dL, LDH > 200 U/L. Infants showed a predominance of mononuclear WBC, while children exhibited a predominance of polymorphonuclear WBC. Glucose levels were higher, and total protein levels were lower in infants compared to children. Age was positively correlated with polymorphonuclear WBC percentage (rho = 0.509, p < 0.001) and protein levels (rho = 0.622, p < 0.001), whereas glucose levels were negatively correlated with age (rho = −0.274, p = 0.043). Conclusions: Age-specific differences in pleural fluid biomarkers were observed in pediatric patients with PPE, suggesting a more robust and acute inflammatory response in children compared to infants. These findings underscore the importance of considering age-related variations in the inflammatory response when diagnosing and managing PPE in pediatric populations.
- 24 April 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (9) , 1086
Open AccessPleural Fluid Biomarkers of Pediatric Parapneumonic Effusion
Background/Objectives: Parapneumonic pleural effusion (PPE) secondary to community-acquired pneumonia is the most common cause of pediatric pleural effusion. This study aimed to evaluate the pleural fluid characteristics of pediatric patients with PPE and to compare biomarkers between infants (1–12 months) and children (1–14 years). Methods: Fifty-four pediatric patients (14 infants and 40 children) with PPE were included. Pleural fluid samples were analyzed for white blood cell (WBC) count, glucose, total protein, lactate dehydrogenase (LDH), adenosine deaminase (ADA), and pH levels. Differences between age groups and correlations between age and pleural fluid biomarkers were assessed. Results: Most pediatric PPE cases exhibited biochemical characteristics consistent with pleural exudate: WBC > 1000 cells/µL, total protein > 3 g/dL, LDH > 200 U/L. Infants showed a predominance of mononuclear WBC, while children exhibited a predominance of polymorphonuclear WBC. Glucose levels were higher, and total protein levels were lower in infants compared to children. Age was positively correlated with polymorphonuclear WBC percentage (rho = 0.509, p < 0.001) and protein levels (rho = 0.622, p < 0.001), whereas glucose levels were negatively correlated with age (rho = −0.274, p = 0.043). Conclusions: Age-specific differences in pleural fluid biomarkers were observed in pediatric patients with PPE, suggesting a more robust and acute inflammatory response in children compared to infants. These findings underscore the importance of considering age-related variations in the inflammatory response when diagnosing and managing PPE in pediatric populations.
- Open Access
- 31 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (7) , 877
Customized Fetal Body Mass Index as a Better Predictive Marker for Neonatal Nutritional Status
Background/Objectives: The diagnosis of fetal nutritional status is of great importance for the accurate evaluation and monitoring of these pregnancies. The objective of the present study is to develop a model that allows for the prenatal assessment of fetal body mass index and to evaluate its diagnostic efficacy in predicting neonatal nutritional status. Methods: A retrospective cohort study was conducted to develop and evaluate a new model in the diagnosis of alterations in fetal nutritional status based on the customized fetal body mass index. By establishing the relationship between weight and length, we can calculate the fetal body mass index, which could correlate more effectively with nutritional status. Results: A total of 12,633 subjects were recruited, and 9499 were included in our study. Capacities to predict both neonatal malnourishment and overnutrition were calculated for each of the three methods analyzed (BMI, GROW, and IG21st). The receiver operating characteristic curve for each method was developed. The sensitivity and specificity for the assessment of malnutrition were 0.83 and 0.90, respectively. The area under the ROC curve of our method was 0.95 for malnutrition, while for IG21st and GROW, it was 0.80 and 0.79, respectively. Conclusions: This study demonstrates a superior diagnostic capacity for alterations in fetal and neonatal nutritional status of this new fetal BMI curve compared to the previously used fetal weight percentile curves.
- 31 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (7) , 877
Open AccessCustomized Fetal Body Mass Index as a Better Predictive Marker for Neonatal Nutritional Status
Background/Objectives: The diagnosis of fetal nutritional status is of great importance for the accurate evaluation and monitoring of these pregnancies. The objective of the present study is to develop a model that allows for the prenatal assessment of fetal body mass index and to evaluate its diagnostic efficacy in predicting neonatal nutritional status. Methods: A retrospective cohort study was conducted to develop and evaluate a new model in the diagnosis of alterations in fetal nutritional status based on the customized fetal body mass index. By establishing the relationship between weight and length, we can calculate the fetal body mass index, which could correlate more effectively with nutritional status. Results: A total of 12,633 subjects were recruited, and 9499 were included in our study. Capacities to predict both neonatal malnourishment and overnutrition were calculated for each of the three methods analyzed (BMI, GROW, and IG21st). The receiver operating characteristic curve for each method was developed. The sensitivity and specificity for the assessment of malnutrition were 0.83 and 0.90, respectively. The area under the ROC curve of our method was 0.95 for malnutrition, while for IG21st and GROW, it was 0.80 and 0.79, respectively. Conclusions: This study demonstrates a superior diagnostic capacity for alterations in fetal and neonatal nutritional status of this new fetal BMI curve compared to the previously used fetal weight percentile curves.
- Open Access
- 11 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (6) , 686
External Validation of a Predictive Model for Thyroid Cancer Risk with Decision Curve Analysis
Background/Objectives: Thyroid cancer ranks among the most prevalent endocrine neoplasms, with a significant rise in incidence observed in recent decades, particularly in papillary thyroid carcinoma (PTC). This increase is largely attributed to the enhanced detection of subclinical cancers through advanced imaging techniques and fine-needle aspiration biopsies. The present study aims to externally validate a predictive model previously developed by our group, designed to assess the risk of a thyroid nodule being malignant. Methods: By utilizing clinical, analytical, ultrasound, and histological data from patients treated at the Puerto Real University Hospital, this study seeks to evaluate the performance of the predictive model in a distinct dataset and perform a decision curve analysis to ascertain its clinical utility. Results: A total of 455 patients with thyroid nodular pathology were studied. Benign nodular pathology was diagnosed in 357 patients (78.46%), while 98 patients (21.54%) presented with a malignant tumor. The most frequent histological type of malignant tumor was papillary cancer (71.4%), followed by follicular cancer (6.1%). Malignant nodules were predominantly solid (95.9%), hypoechogenic (72.4%), with irregular or microlobed borders (36.7%), and associated with suspicious lymph nodes (24.5%). The decision curve analysis confirmed the model’s accuracy and its potential impact on clinical decision-making. Conclusions: The external validation of our predictive model demonstrates its robustness and generalizability across different populations and clinical settings. The integration of advanced diagnostic tools, such as AI and ML models, improves the accuracy in distinguishing between benign and malignant nodules, thereby optimizing treatment strategies and minimizing invasive procedures. This approach not only facilitates the early detection of cancer but also helps to avoid unnecessary surgeries and biopsies, ultimately reducing patient morbidity and healthcare costs.
- 11 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (6) , 686
Open AccessExternal Validation of a Predictive Model for Thyroid Cancer Risk with Decision Curve Analysis
Background/Objectives: Thyroid cancer ranks among the most prevalent endocrine neoplasms, with a significant rise in incidence observed in recent decades, particularly in papillary thyroid carcinoma (PTC). This increase is largely attributed to the enhanced detection of subclinical cancers through advanced imaging techniques and fine-needle aspiration biopsies. The present study aims to externally validate a predictive model previously developed by our group, designed to assess the risk of a thyroid nodule being malignant. Methods: By utilizing clinical, analytical, ultrasound, and histological data from patients treated at the Puerto Real University Hospital, this study seeks to evaluate the performance of the predictive model in a distinct dataset and perform a decision curve analysis to ascertain its clinical utility. Results: A total of 455 patients with thyroid nodular pathology were studied. Benign nodular pathology was diagnosed in 357 patients (78.46%), while 98 patients (21.54%) presented with a malignant tumor. The most frequent histological type of malignant tumor was papillary cancer (71.4%), followed by follicular cancer (6.1%). Malignant nodules were predominantly solid (95.9%), hypoechogenic (72.4%), with irregular or microlobed borders (36.7%), and associated with suspicious lymph nodes (24.5%). The decision curve analysis confirmed the model’s accuracy and its potential impact on clinical decision-making. Conclusions: The external validation of our predictive model demonstrates its robustness and generalizability across different populations and clinical settings. The integration of advanced diagnostic tools, such as AI and ML models, improves the accuracy in distinguishing between benign and malignant nodules, thereby optimizing treatment strategies and minimizing invasive procedures. This approach not only facilitates the early detection of cancer but also helps to avoid unnecessary surgeries and biopsies, ultimately reducing patient morbidity and healthcare costs.
- Open Access
- 16 December 2024
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 51 (12) , 266
Extended Survival and Prognostic Factors in Endometrial Cancer: A Multivariate Cox Regression Analysis
Background: Endometrial cancer (EC) is the third most prevalent neoplasm among women in Spain and the most frequent malignancy of the female genital tract. The primary risk factors are associated with increased estrogen levels. The objective of our study is to determine the current specific progression-free survival (PFS) and overall survival (OS) in patients with EC at the University Hospital of Puerto Real. Additionally, we aim to understand the independent role of specific factors in the risk of recurrence and mortality from EC through a multivariate analysis. Methods: A retrospective observational survival analysis of a case series was conducted. The study population included all women diagnosed and treated for EC in Spain between January 2010 and December 2021. The Kaplan-Meier method and Cox regression analysis were performed to evaluate survival based on patient age, tumor stage, histological type, and degree of differentiation, and to quantify survival probabilities for each factor. Results: A total of 324 patients were included. The PFS was 86.6% at 5 years and 81.1% at 10 years. The OS was 91.3% at 5 years and 84.8% at 10 years. The tumor-related mortality rate was 9.3% (N = 30) and the tumor recurrence rate was 5.6% (N = 18). The estimated median follow-up using the inverse Kaplan-Meier method was 4.33 years (95% confidence interval (95% CI): 3.72–4.94) for OS and 4.57 years (95% CI: 4.05–5.09) for PFS. The statistically significant factors affecting PFS and OS were age ≥60 years at diagnosis, advanced International Federation of Gynecology and Obstetrics (FIGO) stage (II–IV), non-endometrioid tumor, high tumor grade, and lymphovascular space invasion. Multivariate Cox regression analysis shows that being 60 years or older at the time of diagnosis, advanced FIGO stages, high tumor grade, and serous-papillary tumors are independent risk factors for recurrence or death in EC. Conclusions: Our study shows that being 60 years or older at the time of diagnosis, advanced FIGO stages (II–IV), non-endometrioid EC, higher histological tumor grade, and lymphovascular space invasion are associated with lower OS and PFS. Additionally, multivariate Cox analysis suggests that age ≥60 years at diagnosis, advanced FIGO stages, high tumor grade, and serous-papillary histological type are independent prognostic factors influencing survival and recurrence in EC. This study should serve as a foundation for further research, incorporating relevant aspects of the molecular biology of EC to refine patient prognosis.
- 16 December 2024
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 51 (12) , 266
Open AccessExtended Survival and Prognostic Factors in Endometrial Cancer: A Multivariate Cox Regression Analysis
Background: Endometrial cancer (EC) is the third most prevalent neoplasm among women in Spain and the most frequent malignancy of the female genital tract. The primary risk factors are associated with increased estrogen levels. The objective of our study is to determine the current specific progression-free survival (PFS) and overall survival (OS) in patients with EC at the University Hospital of Puerto Real. Additionally, we aim to understand the independent role of specific factors in the risk of recurrence and mortality from EC through a multivariate analysis. Methods: A retrospective observational survival analysis of a case series was conducted. The study population included all women diagnosed and treated for EC in Spain between January 2010 and December 2021. The Kaplan-Meier method and Cox regression analysis were performed to evaluate survival based on patient age, tumor stage, histological type, and degree of differentiation, and to quantify survival probabilities for each factor. Results: A total of 324 patients were included. The PFS was 86.6% at 5 years and 81.1% at 10 years. The OS was 91.3% at 5 years and 84.8% at 10 years. The tumor-related mortality rate was 9.3% (N = 30) and the tumor recurrence rate was 5.6% (N = 18). The estimated median follow-up using the inverse Kaplan-Meier method was 4.33 years (95% confidence interval (95% CI): 3.72–4.94) for OS and 4.57 years (95% CI: 4.05–5.09) for PFS. The statistically significant factors affecting PFS and OS were age ≥60 years at diagnosis, advanced International Federation of Gynecology and Obstetrics (FIGO) stage (II–IV), non-endometrioid tumor, high tumor grade, and lymphovascular space invasion. Multivariate Cox regression analysis shows that being 60 years or older at the time of diagnosis, advanced FIGO stages, high tumor grade, and serous-papillary tumors are independent risk factors for recurrence or death in EC. Conclusions: Our study shows that being 60 years or older at the time of diagnosis, advanced FIGO stages (II–IV), non-endometrioid EC, higher histological tumor grade, and lymphovascular space invasion are associated with lower OS and PFS. Additionally, multivariate Cox analysis suggests that age ≥60 years at diagnosis, advanced FIGO stages, high tumor grade, and serous-papillary histological type are independent prognostic factors influencing survival and recurrence in EC. This study should serve as a foundation for further research, incorporating relevant aspects of the molecular biology of EC to refine patient prognosis.
- Open Access
- 9 August 2024
- Published by Springer Nature in Microchimica Acta
- Vol. 191 (9) , 1-12
New spin coated multilayer lactate biosensor for acidosis monitoring in continuous flow assisted with an electrochemical pH probe
A LOx-based electrochemical biosensor for high-level lactate determination was developed. For the construction of the biosensor, chitosan and Nafion layers were integrated by using a spin coating procedure, leading to less porous surfaces in comparison with those recorded after a drop casting procedure. The analytical performance of the resulting biosensor for lactate determination was evaluated in batch and flow regime, displaying satisfactory results in both modes ranging from 0.5 to 20 mM concentration range for assessing the lactic acidosis. Finally, the lactate levels in raw serum samples were estimated using the biosensor developed and verified with a blood gas analyzer. Based on these results, the biosensor developed is promising for its use in healthcare environment, after its proper miniaturization. A pH probe based on common polyaniline-based electrochemical sensor was also developed to assist the biosensor for the lactic acidosis monitoring, leading to excellent results in stock solutions ranging from 6.0 to 8.0 mM and raw plasma samples. The results were confirmed by using two different approaches, blood gas analyzer and pH-meter. Consequently, the lactic acidosis monitoring could be achieved in continuous flow regime using both (bio)sensors.
- 9 August 2024
- Published by Springer Nature in Microchimica Acta
- Vol. 191 (9) , 1-12
Open AccessNew spin coated multilayer lactate biosensor for acidosis monitoring in continuous flow assisted with an electrochemical pH probe
A LOx-based electrochemical biosensor for high-level lactate determination was developed. For the construction of the biosensor, chitosan and Nafion layers were integrated by using a spin coating procedure, leading to less porous surfaces in comparison with those recorded after a drop casting procedure. The analytical performance of the resulting biosensor for lactate determination was evaluated in batch and flow regime, displaying satisfactory results in both modes ranging from 0.5 to 20 mM concentration range for assessing the lactic acidosis. Finally, the lactate levels in raw serum samples were estimated using the biosensor developed and verified with a blood gas analyzer. Based on these results, the biosensor developed is promising for its use in healthcare environment, after its proper miniaturization. A pH probe based on common polyaniline-based electrochemical sensor was also developed to assist the biosensor for the lactic acidosis monitoring, leading to excellent results in stock solutions ranging from 6.0 to 8.0 mM and raw plasma samples. The results were confirmed by using two different approaches, blood gas analyzer and pH-meter. Consequently, the lactic acidosis monitoring could be achieved in continuous flow regime using both (bio)sensors.